Company Consumer Health · Self-Care
The company you have never heard of makes the toothpaste, painkillers and vitamins you buy without thinking. Here is how GSK's cast-off brands became a £30 billion bet on self-care.
Open your bathroom cabinet. The tube of sensitivity toothpaste, the box of painkillers, the multivitamin you forget to take, the gel you rub on a stiff shoulder - there is a decent chance one company sits behind all of them. That company is Haleon, and until 2022 it did not exist as a name. The brands are old. The company is new. And the gap between those two facts is the whole story.
Haleon is the world's largest standalone consumer-health business. It was carved out of the pharmaceutical giant GSK, listed on two stock exchanges on the same July morning, and handed a portfolio of household names to run on its own. What it sells is deliberately unglamorous: toothpaste, cold remedies, antacids, vitamins, over-the-counter pain relief. What it is betting on is bigger - that more of us will manage our own health, and buy the products to do it.
Strip away the corporate language and Haleon does one thing: it makes and markets everyday health products that you can buy without a prescription. The company organises its whole business into five categories, and each one maps to a shelf you already know.
The brand names carry the weight. Sensodyne, parodontax and Polident cover oral health. Panadol, Advil and Voltaren handle pain. Centrum and Emergen-C sit in vitamins. Theraflu, Otrivin and Flonase manage coughs, colds and allergies. Tums and ENO settle stomachs. You have almost certainly bought several of them; you have almost certainly never noticed they share a parent.
The customer is nearly everyone. Haleon's products reach households across roughly 170 markets through pharmacies, supermarkets, mass retailers and, increasingly, online marketplaces. But there is a second, quieter customer: the professional. Dentists recommend Sensodyne; pharmacists reach for Voltaren; the endorsement of an expert is baked into how these brands are sold.
The problem Haleon frames itself around is self-care - the everyday health decisions people make before, or instead of, seeing a doctor. A sore throat, a headache, a gap in a diet, sensitive teeth. Handled at home, these keep people functioning and, in aggregate, lighten the load on stretched health systems. Haleon has publicly set out to help millions of people a year become more involved in managing their own health. Whether you read that as public-health mission or demand generation, the two point in the same direction.
Haleon did not appear overnight - it was assembled over a decade of dealmaking and then set free in a single day. Three consumer-health businesses were folded together before the spin-off ever happened.
There is a footnote worth its own headline. Before the spin-off, GSK reportedly turned down a bid of around £50 billion from Unilever for these brands. It listed them instead - and the market's opening valuation landed closer to £30 billion. Brave call or expensive one? The share price has been arguing about it ever since.
Haleon runs on fast-moving consumer goods economics applied to healthcare. The products are inexpensive, bought on repeat, and defended by trust rather than novelty. A tube of toothpaste is not a moonshot; a tube of toothpaste bought by the same person for twenty years is a very good business. Scale, clinical backing and brand recognition give Haleon pricing power that a generic private-label version cannot match.
Distribution is spreading. Alongside the pharmacy counter and the grocery shelf, Haleon has leaned into e-commerce, direct-to-consumer channels and a long, ongoing digital and cloud transformation of its operations - the unglamorous plumbing that lets a century-old brand portfolio run on modern data.
Haleon's edge is not a single product - it is focus and trust. As a spin-off, it does one thing where its former parent did many: no prescription pipeline, no research moonshots, just consumer health at global scale. That single-mindedness is the pitch to investors. The moat is the decades of recommendation and habit behind names like Sensodyne and Centrum, which a newcomer cannot buy off the shelf.
| Player | Origin | Signature brands |
|---|---|---|
| Haleon | GSK spin-off (2022) | Sensodyne, Panadol, Centrum |
| Kenvue | J&J spin-off (2023) | Tylenol, Listerine, Neutrogena |
| Reckitt | Long-standing FMCG | Nurofen, Strepsils, Gaviscon |
| Bayer C.H. | Pharma consumer arm | Aspirin, Claritin, Berocca |
The most direct rival, Kenvue, was born the same way one year later - Johnson & Johnson's consumer division, spun into its own company. Two giants, both created by big pharma stepping back from the bathroom cabinet, now competing for the same shelf.
Haleon lives in the aisle between the pharmacy dispensary and the supermarket - close enough to medicine to claim clinical credibility, close enough to groceries to be bought on impulse. It is one of the largest companies on the London market and among the biggest names in a global consumer-health sector worth hundreds of billions. Its expertise is the combination that is hard to copy: pharmaceutical-grade science, FMCG-grade marketing, and a distribution reach that spans roughly 170 markets.
For everyday people, the practical version is simpler than any strategy deck. When you reach for something to whiten sensitive teeth, ease a headache, clear a blocked nose or plug a gap in your diet, you are reaching into Haleon's portfolio - usually without knowing it, and that is exactly how the company likes it.